Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2a, Double Blind, Placebo Controlled, Multicenter, Dose Escalation Study to Evaluate the Safety and Efficacy of BIO 11006 Inhalation Solution in Subjects With Chronic Obstructive Pulmonary Disease

NCT00648245 is registered in ClinicalTrials.gov with BioMarck Pharmaceuticals, Ltd. as lead sponsor.

NCT NCT00648245
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00648245 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2a, Double Blind, Placebo Controlled, Multicenter, Dose Escalation Study to Evaluate the Safety and Efficacy of BIO 11006 Inhalation Solution in Subjects With Chronic Obstructive Pulmonary Disease
Lead sponsor
BioMarck Pharmaceuticals, Ltd.
Phase
Phase 2
Overall status
Completed
Start date
June 30, 2008
Completion date
July 31, 2010
Enrollment
172 (estimated)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

chronic obstructive pulmonary disease, copd